AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Convatec Group PLC

Declaration of Voting Results & Voting Rights Announcements Nov 1, 2017

4959_rns_2017-11-01_4637e8e8-9fac-48d6-a5dd-dd9da964a45a.html

Declaration of Voting Results & Voting Rights Announcements

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1281V

ConvaTec Group PLC

01 November 2017

ConvaTec Group Plc ("the Company") - Total Voting Rights

Reading, United Kingdom (1 November 2017)

The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. On 31 October 2017 the Company's issued capital with voting rights consists of 1,951,850,599 ordinary shares of 10p each.  The Company does not hold any shares in Treasury at the date of this disclosure.

The above figure (1,951,850,599) can be used by shareholders as the denominator for the calculations by which to determine if they are required to notify their interest in, or a change to, their interest in the Company under the UK Financial Conduct Authority's Disclosure and Transparency Rules. 

Enquiries

Media

Bobby Leach, VP Group Corporate Affairs, ConvaTec                        +44 (0)7770 842 226

Alastair Elwen, Finsbury                                                                       +44 (0)207 251 3801

Analysts and Investors

John Crosse, VP Investor Relations, ConvaTec                         +44 (0)7500 141 435

Kirsty Law, Director Investor Relations, ConvaTec                               +44 (0)7470 909 582

[email protected]

ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92

About ConvaTec

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. ConvaTec's products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com where a copy of this announcement can also be found.

This information is provided by RNS

The company news service from the London Stock Exchange

END

TVRZMMFGFMDGNZM

Talk to a Data Expert

Have a question? We'll get back to you promptly.